SUMMARY: A six yea r old girl of Ethiopian origin s uffering from atolJic eczema sim:e the age of two is presented. Prior to a visit to her grandparents in Ethiopia, she receh"ed 250 mg chloroquin e weekly as a prophylaxis against malaria. Three weeks thereafter, she deve loped sharpl y demarcated dcpigmented ~treas on the face, especially in the periorbital area. On returning home to Norway the medication was discontinued, and after a few weeks the first signs of repigmcntation were noti ced. Eight months after cessation of therapy, almost complete re pigmentation had been achieved. Compl ete repigment ation was obsen'ed onc year after th e cessation of chloroquine-thera,)y.
Introduction
Pi gmentation disturbances during .mtimalarial lherapy are common. Twenty five pe r cent of the paliel1l s on chloroquine therapy for more than four months experience these efTects (1). The intensiry of the hyperp igme nlmion vari es from bluish-black in the periorbital and other areas on the face and on the trunk , to grey ovcr the hard palate and subung uaUy. 1n add ition 10 hyperpigmcl1tationlhe bleaching of hair and freck les has bcen desc ribed (2) . Hypopigmcntation of skin during c hloroquine therapy however is a rare event.
We describe a patient who developed vitiligo-like skin lesions on lhe face when taking chloroquine as a malariaprophylaxis, and rev i~w the literatu re concernin g depigmentation during chlorlXJ.uine therapy.
Patient
A six year old girl of Eth iopian origin bUl born in Norway. presented to our department in the spring of 1994 because o f depigmented patches in the f~lce. The otherwise healthy girl had sinee the age of (WO yeaJ3. suffered from atopic eCLema. There wal:i no history of other skin disease in the girl or in her ne'lr family. Es pecially, there was no hi story of aU loimmune skin diseases in the patient or in the famil y. The depigmentation had started when vis iting her grandparents in Eritrea. As a prophylactic agent aga inst malaria. she had been g iven 250 mg chloroquine weekly. She received no other systemic medication nor was any topical therapy used on her face. After three weeks of arllimalarial Iherapy the parcllls not iced the first skin changes in their daughter. The girl experienced no subjective complaints, played as normal.
and got a lot of fre sh ai r and sun. There were no signs o f visual disturbances. In all she received ten lablet" of chloroquine before retu rn ing to Norway. Here the parent<; di scolllinued the medication. After initial treatment with antimycotic ointment, she presented to our depanment. with the class i(.:al features of vitili go (Fig I ) . Clinical controls at one. thre~ (Fig 2) . six and eighl (Fig 3) months showed a rapid ly and, in the end. complete rcpigmcntation of the previous dep igmentcd areas.
Discussion
Hypopigmentation of skin during chloroqui ne treatment has been reported in only fo ur palienls (3) (4) (5) . All patients were black Africans. and had been exposed to the African sun . Two patients from Ghana had been seeking med ical (.:arc because of vis ual di sturbances. Both were on sclfm ed i (':~lIi o n , and had been taking large amount s of chlo roquine over a period of time (3). The patients had developed depigmentation on the face, especiall y on the checks. nose and brows. One also had hyperpigmelllalion of the hard palate. Upon cessation of lhe chloroquine therapy. rcpigmcntation rapidl y occurred, but lhe retinopathy did not group
Another black paJienl. seen in The Netherlands after a trip to tropical Afri ca. developed facial depigmentation (4). He had been taking chloroqu ine as a prophylactic agent against malaria before leaving the Netherlands. After a few months in Africa, he deve loped a pruritic and papular rash. On investigation. the minimal erythema dose in the range about 300 mm was reduced. Photopatch testing with chloroquine and UVA revealed positive resuits.
A further patient, a black South African male , had received chloroq uine s ince the age of 27 for rheumatoid arthritis (5). Two years after initiation of the therapy he noti ced facial depigmentation. C hloroquine was discontinued and he wa\i given vitamin C ( 100 rng daily) as a placebo. After Iwo months, compl ete repigmellla£ion of the prev ious depigmenled areas had occurred. Interestingly, faclOrs whi ch influence the binding of ch loroquine 10 melanin are those lypi cal of cation exchange.
It has been shown that the free radical content of melanin is redu ced by pretreatment with ascorbic acid (6). The medication w ith ascorbic acid may have interfered w ith the drug-melanin complex and hence induced clinical improvement .
The im. : rea!)ed chloroquine concentrations in tiss ues MICh as eye, ear. skin and hair is explain ed by the high affinit y of Ihe drug to melanin (7). Binding of c.hloroquine to me lanin has been clearl y establis hed. both ill vitro (8) . and by whole-body radiometry ill l'/VO (9) . The theoretica l mec hani sm of the complex formation is that of chargetransfer complexes (9), further hypotht:s is co ncern in g the pigmentati on di sturbances observed during chlo roquine therapy. is the possible interaction between chloroquine and mctal s s uch as copper (10) . The toxic effect 01" chloroquine then wou ld be expla ined by interact ion w ith the cop pe r-requirin g e nzyme tyro[) in ase ( 11 ) . The interaction between chloroquine and melan in may ex plain most o f the unwanted !) ide effects of the drug . such as vis ual dis turbanccs. tinnitus and di zziness. hypcr-and hypopigmcntation, In hi sto log ical investigations it has been shown that the hyperp igmentati on which occurs duri ng chlo roquine therapy is due 10 depos ition of the d rug and/or hemosiderin in the skin. Deposi tion of ch loroquine in the hair may be demonstrated as a b lu ish-white fluorescence in the Wood light ( 12) . Hypo pigmemat ion of hair has been reported in several cases. mostl y in fairhaired individua ls. It has been postulated that thi s is due to affinit y o f chl oroquine for the pheomclan in complex. w hi c h is more plentiful in blond and red haircd individuals. Thi s hypothesis is support ed by experimental data ohtailled from investigations in chicks. Smns and Epstcin demonstrated that installation o f chloroquine into the yo lk sac o f red chicks induced hypopi gmentation in the fea thers, whereas thi s \ .... as not the c ase in black chicks (13) . Out of the reported cases, however. are several ind iv idua ls brunelte or dark-haired (14. 15). Onc patient group.bmj.com on November 2, 2017 -Published by http://jramc.bmj.com/ Downloaded from E Selvaag who developed hypopigmentation of the light-exposed hair also developed an increase in the generalized pigmentation. A slate grey discolouration was noticed around his eyes, on the shoulders and neck (15) .
Black skin and exposure to the african sun were features that our patient had in common with the other four patients reported in the literature. Experimental results point towards a phototoxic reaction due to the ingestion of chloroquine. Whether the observed side-effect in our patient was due to the exposure to sunlight seems likely. Discontinuation of the drug therapy did not leave any residues such as scarring or permanent depigmentation. However, sun-protective precautions during therapy with antimalarial drugs would seem to be indicated.
